Archives
-
Tivozanib (AV-951) In Vitro Workflow Guide
2026-08-28
Tivozanib (AV-951) combines picomolar VEGFR-2 potency with a comparatively selective kinase profile, making it useful for dissecting angiogenic signaling and treatment response in cancer models. This workflow emphasizes formulation control, time-resolved viability and death measurements, and combination testing rather than relying on a single endpoint.
-
Iptacopan (LNP023): Reading Complement Signals
2026-08-27
Iptacopan (LNP023) offers a precise way to interrogate alternative-pathway amplification through reversible factor B inhibition. This article connects convertase biology with assay selection, disease-model interpretation, and translational complement research.
-
Imidazoline Antagonists and β-Cell K+ Channels
2026-08-27
The reference study showed that alinidine, antazoline, phentolamine, and Tolazoline increase insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than solely by blocking α2-adrenoceptors. Its combined use of 86Rb efflux, whole-cell patch clamp, and pharmacological rescue experiments provides a useful framework for interpreting imidazoline effects in islet function research.
-
Iptacopan Monotherapy in PNH: Evidence and Methods
2026-08-26
The reference study provides early clinical proof of concept that oral, single-agent factor B inhibition with Iptacopan (LNP023) can rapidly reduce hemolysis in treatment-naive patients with paroxysmal nocturnal hemoglobinuria. Its two-cohort design links proximal alternative pathway blockade with improvements in lactate dehydrogenase, hemoglobin, and transfusion status, while also defining important limitations for later controlled trials.
-
S-Adenosylhomocysteine in Translational Research
2026-08-26
S-Adenosylhomocysteine (SAH) is more than a methylation-cycle by-product: it is a mechanistic lever for testing how methylation potential, metabolic state, and cell fate interact. This article connects SAH biology with radiation-associated neural differentiation while defining practical boundaries between evidence, hypothesis, and translational opportunity.
-
Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells
2026-08-25
The reference study developed a phenotypic macrophage screen to identify small molecules that reduce SPP1 expression, then incorporated promising hits into a TAM-avid systemic nanoconstruct. Its lead compound, CANDI460, lowered SPP1 in vitro and in vivo and reduced tumor burden across murine models, supporting myeloid-state reprogramming as a therapeutic strategy.
-
3X FLAG Peptide: From Tag to Translation
2026-08-25
The 3X (DYKDDDDK) Peptide is more than a detection reagent: it is a strategic control point for recombinant protein quality, structural biology, and translational assay design. This article connects the mechanistic lessons of NINJ1 membrane rupture research with practical guidance for affinity purification, immunodetection, protein crystallization, and metal-sensitive workflows.
-
Batimastat (BB-94) Workflows for MMP Research
2026-08-24
Batimastat (BB-94) combines broad-spectrum MMP inhibition with a practical workflow for separating proteolysis, extracellular-matrix remodeling, and cell-intrinsic effects. This guide connects biochemical assays with localized BDNF-processing studies, neuromuscular-junction models, and preclinical tumor research while emphasizing controls and troubleshooting.
-
Vasopressin Analogues: Mechanisms and Translation
2026-08-24
The reference review explains how structural changes to vasopressin reshape receptor selectivity, metabolic stability, duration of action, and therapeutic potential. Its comparison of lypressin, desmopressin, terlipressin, ornipressin, and non-peptide ligands provides a framework for designing receptor, endocrine, vascular, and exploratory antiviral studies.
-
Obeticholic Acid for FXR Liver Research
2026-08-23
Obeticholic Acid provides a mechanism-focused way to activate FXR, quantify bile acid homeostasis, and connect hepatocyte transcriptional responses with liver fibrosis and inflammation endpoints. This practical workflow shows how to use it alongside the Notch–NK findings from a recent fibrosis study without overinterpreting cross-pathway evidence.
-
PTPN2 Targets the STING–STAT3 Axis in Psoriasis
2026-08-22
A 2026 Immunobiology study identifies PTPN2 as a negative regulator of the STING–STAT3 pathway in psoriasis-like inflammation. Using keratinocyte and imiquimod-induced mouse models, the authors show that PTPN2 suppresses inflammatory signaling while promoting autophagy and apoptosis, with additional benefit from rapamycin.
-
Rotigotine hydrochloride for PD Research
2026-08-22
Build route-aware Parkinson’s disease and neuroprotection workflows with Rotigotine hydrochloride, from SH-SY5Y screening to 6-OHDA cystometry. The reference study shows why intravenous and subcutaneous exposure should not be treated as interchangeable when studying motor or lower-urinary-tract phenotypes.
-
Zoledronic Acid: Cancer and Bone Workflows
2026-08-21
Build more reproducible Zoledronic Acid experiments by connecting dose–time apoptosis profiling with bone-disease endpoints and formulation controls. This practical guide distinguishes nominal exposure from delivered exposure across breast cancer, myeloma, and osteolytic disease models.
-
Bufalin-CRISPR Nanomedicine Reprograms CRC Immunity
2026-08-20
Liu et al. describe a calcium lactate nanoparticle that co-delivers bufalin and a CD47-targeting CRISPR/Cas9 ribonucleoprotein for colorectal cancer. The platform combines tumor-cell pyroptosis and apoptosis with macrophage M1 reprogramming and enhanced phagocytosis, providing a mechanistic framework for local and systemic antitumor immunity.
-
LGK-974: From Wnt Blockade to Phenotype
2026-08-20
LGK-974 is a selective PORCN inhibitor that connects Wnt pathway target engagement with measurable tissue and tumor phenotypes. This article uses recent sclerosteosis research to develop a cross-domain framework for interpreting LGK-974 assays in cancer and bone biology.